Tectonic Therapeutic, Inc.
TECX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$20.07
KIRA · Stoqly’s AI analyst, in plain words
- Tectonic Therapeutic, Inc. lost $74.2M in fiscal 2025.
- Free cash flow was −$60.3M in fiscal 2025, — of revenue.
Market cap
$381M
P/E
—
Revenue
—
Net income
−$74.2M
Free cash flow
−$60.3M
Operating margin
—
Tectonic Therapeutic, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$74.2M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Tectonic Therapeutic, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Tectonic Therapeutic, Inc.
- CIK
- 0001681087
Tectonic Therapeutic, Inc. · TECX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$119M | −$106M | −$42.8M | −$58.0M | −$74.2M |
| Diluted EPS | −$2.78 | −$2.42 | −$33.76 | −$6.83 | −$4.05 |
| Cash | |||||
| Cash from operations | −$98.0M | −$97.2M | −$40.7M | −$59.1M | −$60.1M |
| Capital expenditure | $2.5M | $0.3M | $0.3M | $0.2M | $0.2M |
| Free cash flow | −$100M | −$97.5M | −$41.0M | −$59.2M | −$60.3M |
| Share count change | −99.9% | 101,855.7% | −97.1% | 569.3% | 115.8% |
| Debt and strength | |||||
| Cash and short-term investments | $190M | $92.6M | $28.8M | $141M | $254M |
| Debt incl. finance leases | $15.0M | $15.0M | — | — | — |
| Shareholders' equity | $169M | −$45.7M | −$84.6M | $141M | $251M |
| Current ratio | 10.3x | 7.6x | 0.8x | 12.6x | 26.6x |
| Interest coverage | −585.4x | −58.3x | −293.7x | −542.2x | −1,333.9x |
| Returns and quality | |||||
| Return on equity | −56.2% | −171.0% | — | −206.6% | −37.8% |
| Return on tangible equity | −70.3% | — | — | −41.2% | −29.5% |
| Piotroski F-score | — | 1 | — | — | — |
| Altman Z'' | 0.9 | −18.4 | −18.8 | 12.3 | 28.5 |
Insiders bought, 12 months
$0.2M
2 insiders
Insiders sold, 12 months
$0.7M
2 insiders
Of sales under plans
100%
$0.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Tectonic Therapeutic, Inc. · TECX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $20.07 a share, the company is worth $381M.
Source: SEC EDGAR XBRL filings (CIK 0001681087). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.